Claims

1. An immunogenic composition comprising

(i) a MERS-CoV nanoparticle, wherein the nanoparticle comprises a MERS CoV antigen, wherein the antigen consists of baculovirus-expressed full-length Spike polypeptide in trimer form; and wherein the Spike polypeptide is the only polypeptide in the nanoparticle, and

(ii) an adjuvant, wherein the adjuvant consists of two ISCOM matrix particle types wherein the first particle type comprises Matrix A, and the second particle type comprises Matrix C;

wherein the composition is capable of inducing neutralizing antibodies against MERS-CoV.

2. The composition of claim 1, wherein the concentration of the nanoparticle is about 20 μg/mL to about 60 μg/mL.

3. The composition of claim 2, wherein the concentration of the nanoparticle is about 30 μg/mL to about 50 μg/mL.

4. The composition of claim 1, wherein the Spike polypeptide consists of SEQ ID NO: 2.

5. The composition of claim 1, wherein the nanoparticle of the immunogenic composition comprises about five trimers to about 30 trimers of the Spike polypeptide.

6. The composition of claim 5, wherein the nanoparticle of the immunogenic composition comprises about ten trimers to about 20 trimers of the Spike polypeptide.

7. The composition of claim 1, wherein the Spike polypeptide in the immunogenic composition comprises SEQ ID NO: 2.